Leaflet DACARBAZINE MAYNE 200mg powder for solution for injection / infusion

Indicated for: cancer

Route of administration: injectable / infusion

Substance: dacarbazine (alkylating antineoplastic agent)

ATC: L01AX04 (Antineoplastic and immunomodulating agents | Alkylating agents | Other alkylating agents)

Precautions:
Fertility warning
Fertility warning

This medicine may affect fertility.

Dose adjustment in hepatic impairment
Dose adjustment in hepatic impairment

Dose adjustment may be needed in liver disease.

Cytotoxic / special handling
Cytotoxic / special handling

Handle with special care.

Contraception required
Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding
Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis
Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring
Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Severe skin reactions
Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Dacarbazine is a chemotherapy medication used for the treatment of malignant melanoma, Hodgkin's disease, and other types of cancer. It acts as an alkylating agent, interfering with DNA synthesis and inhibiting cell division.

The medication is administered via intravenous infusion, with the dose determined by the physician based on the type of cancer and the patient's overall condition. Common side effects include nausea, vomiting, fatigue, and bone marrow suppression.

Dacarbazine is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with hepatic or renal impairment.

This medication is an important option in cancer treatment, helping to reduce tumor size and improve the prognosis of affected patients.

General data about DACARBAZINE MAYNE 200mg

  • Substance: dacarbazine
  • Date of latest medicines list: 01-10-2013
  • Product code: W59795001
  • Concentration: 200mg
  • Pharmaceutical form: powder for solution for injection / infusion
  • Quantity: 1
  • Product type: Generic medicine
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Concentrations available for dacarbazine

  • 1000mg
  • 100mg
  • 200mg
  • 500mg